Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resouce-limited West Africa

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 476-483

  Gottlieb, Geoffrey S ^a,d   Badiane, Ndeye Mery Dia ^c   Hawes, Stephen E ^b   Fortes, Louise ^c   Toure, Macoumba ^c   Ndour, Cheikh T ^c   Starling, Alison K ^a   Traore, Fatou ^c   Sall, Fatima ^c   Wong, Kim G ^a   Cherne, Stephen L ^a   Anderson, Donovan J ^a   Dye, Stefanie A ^a   Smith, Robert A ^a   Mullins, James I ^a   Kiviat, Nancy B ^a   Sow, Papa Salif ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; I54M GENE; I82F GENE; K65R GENE; K7R GENE; L90M GENE; L99F GENE; LONGITUDINAL STUDY; M184V GENE; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; Q151M GENE; RESOURCE ALLOCATION; SENEGAL; STRAIN IDENTIFICATION; STRUCTURAL GENE; V62A GENE; VIRUS GENE; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-2; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; SENEGAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL LOAD;

EID: 58749087228     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596504     Document Type: Article

References (39)

1. De Cock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. JAMA 1993; 270:2083-6.
2. Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411-7.
3. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
4. Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-6.
5. + T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905-14.
6. Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593-601.
7. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979-90.
8. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. June 2002. Available at: http://www.who.int/ hiv/pub/prev-care/en/ScalingUp-E.pdf. Accessed 14 July 2008.
9. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Therapy 2004; 9:57-65.
10. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347-8.
11. Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 2008; 52:329-32.
12. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-8.
13. Gottlieb GS, Eholie SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069-72; discussion, 73-4.
14. Clark NM, Dieng Sarr A, Sankale JL, et al. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS 1998; 12:2506-7.
15. Mullins C, Eisen G, Popper S, et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38:1771-9.
16. Matheron S, Damond F, Benard A, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-62.
17. + cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17(Suppl 3):S49-54.
18. Ndour CT, Batista G, Manga NM, et al. Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study [in French]. Medecine et Maladies Infectieuses 2006; 36:111-4.
19. Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455-8.
20. Smith R, Gottlieb G, Anderson D, Pyrak C, Preston B. Three amino acid changes are sufficient for broad-spectrum nucleoside analog resistance in HIV-2 [abstract 263]. In: Cold Spring Harbor Meeting on Retroviruses (New York). 2008.
21. Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu/. Accessed 14 July 2008
22. Gottlieb GS, Hawes SE, Wong KG, et al. HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal. AIDS Res Hum Retroviruses 2008; 24:857-64.
23. Ruelle J, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infectious Diseases 2008; 8:21.
24. Ntemgwa M, Brenner B, Toni T, et al. The role of innate polymorphisms in drug-selected reverse transcriptase mutations in HIV-1 and HIV-2 subtypes [abstract 887]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
25. van der Ende ME, Guillon C, Boers PH, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25:11-8.
26. Damond F, Collin G, Matheron S, et al. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antiviral Therapy 2005; 10:861-5.
27. Stanford University HIV Drug Resistance Database. Genotypic resistance interpretation algorithm. Available at: http://hivdb.stanford.edu/pages/algs/ HIVdb.html. Accessed 14 July 2008.
28. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201.
29. Rodes B, Toro C, Colombatti R, et al. Selection of the K65R mutation in HIV-2 patients exposed to abacavir [abstract 885]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
30. Pieniazek D, Rayfield M, Hu DJ, et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18:495-502.
31. Damond F, Brun-Vezinet F, Matheron S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43:484-7.
32. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709-13.
33. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71:298-305.
34. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007; 51:604-10.
35. Colson P, Henry M, Tourres C, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in southern France. J Clin Microbiol 2004; 42:570-7.
36. M'Barek NB, Audoly G, Raoult D, Gluschankof P. HIV-2 protease resistance defined in yeast cells. Retrovirology 2006; 3:58.
37. Vergne L, Kane CT, Laurent C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003; 17(Suppl 3):S31-8.
38. Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21.
39. Ariyoshi K, Jaffar S, Alabi AS, et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS 2000; 14:339-44.